Gene replacement strategies for treating non-small cell lung cancer

Seminars in Radiation Oncology

Volumn 10, Issue 4, 2000, Pages 333-342

  Roth, Jack A ^a,b,c,d   Grammer, Susan F ^a,b,c,d   Swisher, Stephen G ^a,b,c,d   Nemunaitis, John ^a,b,c,d   Merritt, James ^a,b,c,d   Meyn Jr, Raymond E ^a,b,c,d  

^a Department of Thoracic and Cardiovascular Surgery ^*  (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Introgen Therapeutics Inc   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; PROTEIN P53; VIRUS VECTOR;

ADENOVIRUS; APOPTOSIS; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; DNA DAMAGE; FEVER; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RETROVIRUS; REVIEW; TUMOR CELL; TUMOR SUPPRESSOR GENE;

EID: 0033789477     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2000.9127     Document Type: Article

References (68)

1. Cancer statistics, 1997
2. A new international staging system for lung cancer
3. Survival in early-stage non-small cell lung cancer
4. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer
5. Radiation-induced apoptosis: Relevance to radiotherapy
6. Apoptosis and response to radiation: Implications for radiation therapy
7. Apoptosis in murine tumors treated with chemotherapy agents
8. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effects
9. Adenovirus-mediated wild-type p53 gene transfer downregulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer
10. Adenoviral-mediated p53 gene transfer in advanced non-small cell lung cancer
11. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes
12. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer
13. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection
14. Accumulation of p53 tumor-suppressor gene protein: An independent marker of prognosis in breast cancers
15. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer
16. p53 expression and prognosis in gastric carcinoma
17. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers
18. WAF1, a potential mediator of p53 tumor suppression
19. Tumor suppressor p53 is a direct transcriptional activator of human bax gene
20. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression
21. The p53 pathway and apoptosis
22. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line
23. Bcl-2 blocks p53-dependent apoptosis
24. Inhibition of p53 transcriptional activity by bcl-2 requires its membrane-anchoring domain
25. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis
26. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
27. Association with Cdc2 and inhibition of Cdc2/cyclin B1 kinase activity by the p53-regulated protein Gadd45
28. Cell surface trafficking of fas: A rapid mechanism of p53-mediated apoptosis
29. p53-Dependent DNA damage-induced apoptosis requires fas/APO-1-independent activation of CPP32B1
30. A model for p53-induced apoptosis
31. A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis
32. Involvement of p85 in p53-dependent apoptotic response to oxidative stress
33. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model
34. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus
35. In vivo adenovirus-mediated p53 tumor-suppressor gene therapy for colorectal cancer
36. Adenovirus-mediated wild-type p53 tumor-suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer
37. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
38. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts
39. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity
40. Adenovirus-mediated gene transfer to human breast tumor cells: An approach for cancer gene therapy and bone marrow purging
41. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis
42. Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model
43. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
44. Clinical protocol: Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin
45. Gene therapy for non-small cell lung cancer: A preliminary report of a phase I trial of adenoviral p53 gene replacement
46. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumor injection of an adenovirus vector expressing wildtype p53 (Ad-p53)
47. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
48. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
49. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients
50. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6
51. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53
52. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line
53. Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer
54. Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome
55. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation
56. Role of p53 in the regulation of irradiation-induced apoptosis in neuroblastoma cells
57. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
58. Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: Can they predict treatment response and clinical outcome?
59. Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction
60. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis
61. bcl-2 Family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy
62. Adenovirus-mediated p53 gene therapy for human gliomas
63. Novel approaches to the treatment of small-cell lung cancer
64. p53 Mutation does not correlate with radiosensitivity in 24 head and neck cancer cells lines
65. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage
66. No association between radiosensitivity and TP53 status, G(1) arrest or protein levels of p53, myc, ras or raf in human melanoma lines
67. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism
68. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies